Generalized anxiety disorder Trials in Memphis, United States
Conditions / Generalized anxiety disorder / Memphis, United States
Generalized anxiety disorder has been the subject of sustained clinical investigation across multiple research sites.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00235508 | Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder | COMPLETED | PHASE4 |
| NCT00481325 | Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder | COMPLETED | PHASE2/PHASE3 |
| NCT00329264 | Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder | COMPLETED | PHASE3 |
| NCT00616655 | Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects | COMPLETED | PHASE2 |
| NCT00730691 | Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder | COMPLETED | PHASE3 |
| NCT03829241 | Randomized Trial of Adult Participants With Generalized Anxiety Disorder | COMPLETED | PHASE3 |
| NCT00735267 | A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD) | TERMINATED | PHASE3 |
| NCT00329446 | Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder | COMPLETED | PHASE3 |
| NCT06741228 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | ACTIVE_NOT_RECRUITING | — |
| NCT00658008 | A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1) | TERMINATED | PHASE3 |